Metastases-Targeting Radiotherapy and ADT-Reply

Alexander D Sherry¹, Paul G Corn², Chad Tang^{3

4

5}

Affiliations

¹ Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
² Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.
³ Department of Genitourinary Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
⁴ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston.
⁵ Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Comment

Alexander D Sherry et al. JAMA Oncol. 2023.

. 2023 Nov 1;9(11):1587-1588.

doi: 10.1001/jamaoncol.2023.3631.

Alexander D Sherry¹, Paul G Corn², Chad Tang^{3

4

5}

¹ Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
² Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.
³ Department of Genitourinary Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
⁴ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston.
⁵ Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.

No abstract available

Comment on

Metastases-Targeting Radiotherapy and ADT.
Liu JM, Kao YS. Liu JM, et al. JAMA Oncol. 2023 Nov 1;9(11):1587. doi: 10.1001/jamaoncol.2023.3628. JAMA Oncol. 2023. PMID: 37707830 No abstract available.